BioSpace News Archive

Metagenomics is defined as the extensive study of various types of genetic material recovered directly from environmental samples, which is further used for many purposes such as identification of a microbial species, classification of microorganisms, and understanding their importance on the planet dating back to their origin.

The global patient handling equipment market has been anticipated in a report by Transparency Market Research to bear a highly competitive landscape for the next few years.

Owing to the presence of a limited key players, the global optical microscopes market is likely to be extremely competitive.

The demand within the global market for infusion pumps has been rising on account of advancements in the domain of healthcare over the past decade, finds Transparency Market Research.

The global dental cement market was valued at approximately US$ 785.4 Mn in 2016 is projected to register cumulative annual growth rate of over 4.8% from 2017 to 2025, according to a new report published by Transparency Market Research titled “Dental Cement Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.

The global flow cytometry market depicts the presence of a highly consolidated market, says Transparency Market Research on the basis of a recently published report.

Neurological diseases have affected millions around the globe, and are known to be one of the worst kinds of maladies that can strike absolutely anyone.

The global market for cervical dysplasia features a highly consolidated competitive landscape, with the top three companies accounting for more than three-fourth of the overall market in 2017, observes a recent report by Transparency Market Research.

Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce the appointment of Martin Andrews as a Non-Executive Director.

Atara Biotherapeutics, Inc. announced the pricing of an underwritten public offering of 12,633,039 shares of its common stock at a price to the public of $11.32 per share and, to certain investors, pre-funded warrants to purchase 2,866,961 shares of its common stock at a purchase price of $11.3199 per pre-funded warrant share, which represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant share.